Figure 5From: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensOS in the four subgroups of the A24 (+) group classified by the number of the peptides showing the positive CTL responses. The A24(+) patient group was classified into 4 groups according to the number of peptide antigens which induced the CTL responses (0, 1, 2 and 3). The OS tended to be better when the number of the peptides that induced CTL responses was higher.Back to article page